On these bases, a recent study focused on the development of third generation anti-TRBC1 CAR T cells, containing CD28 and OX40 co-stimulatory domains, to selectively recognize TRBC1+ cells in vitro and in vivo leukemia models. Here, TRBC1 is linked to leukemia.